Richard H. J. Beǵent

9.2k total citations
182 papers, 6.0k citations indexed

About

Richard H. J. Beǵent is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Richard H. J. Beǵent has authored 182 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Radiology, Nuclear Medicine and Imaging, 58 papers in Molecular Biology and 38 papers in Oncology. Recurrent topics in Richard H. J. Beǵent's work include Monoclonal and Polyclonal Antibodies Research (72 papers), Radiopharmaceutical Chemistry and Applications (52 papers) and Glycosylation and Glycoproteins Research (32 papers). Richard H. J. Beǵent is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (72 papers), Radiopharmaceutical Chemistry and Applications (52 papers) and Glycosylation and Glycoproteins Research (32 papers). Richard H. J. Beǵent collaborates with scholars based in United Kingdom, United States and Australia. Richard H. J. Beǵent's co-authors include Gordon Rustin, E.S. Newlands, K. D. Bagshawe, Kerry Chester, L. Holden, RB Pedley, G Boxer, P A Keep, K D Bagshawe and Aiden Flynn and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Richard H. J. Beǵent

179 papers receiving 5.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard H. J. Beǵent United Kingdom 45 2.2k 2.1k 1.3k 1.2k 1.0k 182 6.0k
D Maraninchi France 47 816 0.4× 1.3k 0.6× 3.8k 2.8× 1.1k 0.9× 404 0.4× 259 8.5k
George L. Wright United States 42 1.1k 0.5× 2.5k 1.2× 837 0.6× 755 0.6× 523 0.5× 135 6.8k
Nancy Hunter United States 46 1.2k 0.5× 2.0k 1.0× 2.7k 2.0× 221 0.2× 620 0.6× 123 6.7k
Michael Peckham United Kingdom 46 892 0.4× 2.2k 1.0× 1.8k 1.3× 682 0.6× 3.7k 3.6× 175 8.0k
Thomas M. Grogan United States 52 846 0.4× 3.1k 1.5× 5.0k 3.7× 293 0.2× 733 0.7× 160 9.2k
Stephan D. Voss United States 46 893 0.4× 2.1k 1.0× 1.7k 1.3× 370 0.3× 732 0.7× 173 6.8k
William T. Barry United States 47 807 0.4× 2.1k 1.0× 4.3k 3.2× 628 0.5× 550 0.5× 191 8.4k
Bayard D. Clarkson United States 51 442 0.2× 3.3k 1.5× 2.3k 1.7× 1.4k 1.2× 501 0.5× 156 9.4k
Franco Cavalli Switzerland 43 1.1k 0.5× 1.5k 0.7× 5.0k 3.7× 511 0.4× 1.0k 1.0× 190 11.6k
Jerry A. Katzmann United States 54 1.2k 0.6× 5.1k 2.4× 2.6k 2.0× 244 0.2× 607 0.6× 171 10.6k

Countries citing papers authored by Richard H. J. Beǵent

Since Specialization
Citations

This map shows the geographic impact of Richard H. J. Beǵent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard H. J. Beǵent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard H. J. Beǵent more than expected).

Fields of papers citing papers by Richard H. J. Beǵent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard H. J. Beǵent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard H. J. Beǵent. The network helps show where Richard H. J. Beǵent may publish in the future.

Co-authorship network of co-authors of Richard H. J. Beǵent

This figure shows the co-authorship network connecting the top 25 collaborators of Richard H. J. Beǵent. A scholar is included among the top collaborators of Richard H. J. Beǵent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard H. J. Beǵent. Richard H. J. Beǵent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
González-Beltrán, Alejandra, et al.. (2011). Establishing a knowledge trail from molecular experiments to clinical trials. New Biotechnology. 28(5). 464–480. 1 indexed citations
2.
Turner, Nicholas C., Sandra J. Strauss, Debashis Sarker, et al.. (2010). Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. British Journal of Cancer. 102(7). 1106–1112. 141 indexed citations
3.
Dancey, Gairin, John Violet, Alessandra Malaroda, et al.. (2009). A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clinical Cancer Research. 15(24). 7701–7710. 28 indexed citations
4.
Mayer, Astrid, Surinder K. Sharma, Berend Tolner, et al.. (2008). Evidence of efficacy of antibody directed enzyme prodrug therapy (ADEPT) in a Phase I trial in patients with advanced carcinoma.. Cancer Research. 68. 2 indexed citations
5.
Green, Alan, Aiden Flynn, RB Pedley, Jason L.J. Dearling, & Richard H. J. Beǵent. (2004). Nonuniform Absorbed Dose Distribution in the Kidney: The Influence of Organ Architecture. Cancer Biotherapy and Radiopharmaceuticals. 19(3). 371–377. 9 indexed citations
6.
7.
Flynn, Aiden, RB Pedley, Alan J. Green, et al.. (2001). Optimizing Radioimmunotherapy by Matching Dose Distribution with Tumor Structure using 3D Reconstructions of Serial Images. Cancer Biotherapy and Radiopharmaceuticals. 16(5). 391–400. 9 indexed citations
8.
Boxer, G, Richard H. J. Beǵent, Jamal Zweit, et al.. (2001). In-vitro uptake of radioactive lipiodol I-131 and I-125 by hepatoblastoma: implications for targeted radiotherapy. Pediatric Surgery International. 17(8). 609–613. 4 indexed citations
9.
Chester, Kerry, Astrid Mayer, L. Robson, et al.. (2000). Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemotherapy and Pharmacology. 46(S1). S8–S12. 36 indexed citations
10.
Mayer, A, Kerry Chester, Aiden Flynn, & Richard H. J. Beǵent. (1999). Taking engineered anti-CEA antibodies to the clinic. Journal of Immunological Methods. 231(1-2). 261–273. 31 indexed citations
11.
12.
Pedley, RB, R Boden, G Boxer, et al.. (1996). Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.. UCL Discovery (University College London). 56(14). 3293–300. 67 indexed citations
13.
Ledermann, Jonathan A., L. Holden, ES Newlands, et al.. (1994). The long‐term outcome of patients who relapse after chemotherapy for non‐seminomatous germ cell tumours. British Journal of Urology. 74(2). 225–230. 7 indexed citations
14.
Dawson, Peter, et al.. (1991). The value of radioimmunoguided surgery in first and second look laparotomy for colorectal cancer. Diseases of the Colon & Rectum. 34(3). 217–222. 21 indexed citations
15.
Sensky, Tom, Amy Gilbert, Richard H. J. Beǵent, et al.. (1989). Physicians' Perceptions of Anxiety and Depression among Their Outpatients: Relationships with Patients and Doctors' Satisfaction with Their Interviews. Journal of the Royal College of Physicians of London. 23(1). 33–38. 27 indexed citations
16.
17.
Crawford, S. M., JA Ledermann, Wajdi Turkie, et al.. (1986). Is ectopic production of human chorionic gonadotrophin (hCG) or alpha fetoprotein (AFP) by tumours a marker of chemosensitivity?. European Journal of Cancer and Clinical Oncology. 22(12). 1483–1487. 16 indexed citations
18.
Herxheimer, Andrew, Richard H. J. Beǵent, & I. C. Walton. (1985). The short life of a terminal care support team. BMJ. 291(6492). 411.1–411. 2 indexed citations
19.
Herxheimer, Andrew, et al.. (1985). The short life of a terminal care support team: experience at Charing Cross Hospital.. BMJ. 290(6485). 1877–1879. 13 indexed citations
20.
Rubens, R.D., Richard H. J. Beǵent, R. Knight, Sheila Sexton, & John L. Hayward. (1978). Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer. 42(4). 1680–1686. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D Maraninchi Breakdown of academic impact, for papers by George L. Wright Breakdown of academic impact, for papers by Nancy Hunter Breakdown of academic impact, for papers by Michael Peckham Breakdown of academic impact, for papers by Thomas M. Grogan Breakdown of academic impact, for papers by Stephan D. Voss Breakdown of academic impact, for papers by William T. Barry Breakdown of academic impact, for papers by Bayard D. Clarkson Breakdown of academic impact, for papers by Franco Cavalli Breakdown of academic impact, for papers by Jerry A. Katzmann
Rankless by CCL
2026